Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: Relationship to MRI findings and anti-neuronal antibodies

Kristen Hayward, Rita J. Jeremy, Sheila Jenkins, Anthony J. Barkovich, Sakir Gultekin, Joel Kramer, Mary Crittenden, Katherine K. Matthay

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Objectives: Opsoclonus-myoclonus-ataxia (OMA) syndrome affects 2% to 3% of patients with neuroblastoma. This study examined relationships between long-term neurobehavioral outcomes and potential biologic markers of OMA, including chronic changes on magnetic resonance imaging (MRI) brain scanning and prevalence of late antineuronal antibodies. Study design: Children with neuroblastoma and OMA were identified through medical record review of patients treated at the University of California at San Francisco Medical Center from 1979 to 1999. Eleven patients with a mean follow-up time of 7.6 years underwent standard neurologic, neurocognitive/developmental, behavioral, and academic assessments. Consenting patients underwent MRI brain scanning and a blood draw. Sera were analyzed for the presence of antineuronal immunoreactivity. Results: Two (18%) patients had no observed neurologic abnormalities, 7 (64%) demonstrated mild deficits, and 2 (18%) had severe neurologic deficits. However, on neurocognitive, behavioral, and academic assessments, 6 (55%) children performed within the average range, 1 (9%) was moderately below average and 4 (36%) had severe cognitive and behavioral deficiencies. Brain MRI in 5 of 5 patients was notable for cerebellar atrophy without supratentorial involvement. Antineuronal activity was detected in sera of 0 of 10 children at follow-up. Conclusions: Certain patients with neuroblastoma associated OMA may achieve average-range neurobehavioral function in spite of residual neurologic abnormalities, with suggestion of continued improvement over time. Late cerebellar atrophy appears to be a common finding regardless of neurologic outcome, whereas antineuronal immune reactivity does not appear to be a long-term feature of OMA.

Original languageEnglish (US)
Pages (from-to)552-559
Number of pages8
JournalJournal of Pediatrics
Volume139
Issue number4
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Opsoclonus-Myoclonus Syndrome
Neuroblastoma
Anti-Idiotypic Antibodies
Magnetic Resonance Imaging
Nervous System Malformations
Neurologic Manifestations
Atrophy
Brain
San Francisco
Serum
Nervous System
Medical Records
Biomarkers
Antibodies

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome : Relationship to MRI findings and anti-neuronal antibodies. / Hayward, Kristen; Jeremy, Rita J.; Jenkins, Sheila; Barkovich, Anthony J.; Gultekin, Sakir; Kramer, Joel; Crittenden, Mary; Matthay, Katherine K.

In: Journal of Pediatrics, Vol. 139, No. 4, 2001, p. 552-559.

Research output: Contribution to journalArticle

Hayward, Kristen ; Jeremy, Rita J. ; Jenkins, Sheila ; Barkovich, Anthony J. ; Gultekin, Sakir ; Kramer, Joel ; Crittenden, Mary ; Matthay, Katherine K. / Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome : Relationship to MRI findings and anti-neuronal antibodies. In: Journal of Pediatrics. 2001 ; Vol. 139, No. 4. pp. 552-559.
@article{bf2950d1b068416f8f72b899ebdf9dcf,
title = "Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: Relationship to MRI findings and anti-neuronal antibodies",
abstract = "Objectives: Opsoclonus-myoclonus-ataxia (OMA) syndrome affects 2{\%} to 3{\%} of patients with neuroblastoma. This study examined relationships between long-term neurobehavioral outcomes and potential biologic markers of OMA, including chronic changes on magnetic resonance imaging (MRI) brain scanning and prevalence of late antineuronal antibodies. Study design: Children with neuroblastoma and OMA were identified through medical record review of patients treated at the University of California at San Francisco Medical Center from 1979 to 1999. Eleven patients with a mean follow-up time of 7.6 years underwent standard neurologic, neurocognitive/developmental, behavioral, and academic assessments. Consenting patients underwent MRI brain scanning and a blood draw. Sera were analyzed for the presence of antineuronal immunoreactivity. Results: Two (18{\%}) patients had no observed neurologic abnormalities, 7 (64{\%}) demonstrated mild deficits, and 2 (18{\%}) had severe neurologic deficits. However, on neurocognitive, behavioral, and academic assessments, 6 (55{\%}) children performed within the average range, 1 (9{\%}) was moderately below average and 4 (36{\%}) had severe cognitive and behavioral deficiencies. Brain MRI in 5 of 5 patients was notable for cerebellar atrophy without supratentorial involvement. Antineuronal activity was detected in sera of 0 of 10 children at follow-up. Conclusions: Certain patients with neuroblastoma associated OMA may achieve average-range neurobehavioral function in spite of residual neurologic abnormalities, with suggestion of continued improvement over time. Late cerebellar atrophy appears to be a common finding regardless of neurologic outcome, whereas antineuronal immune reactivity does not appear to be a long-term feature of OMA.",
author = "Kristen Hayward and Jeremy, {Rita J.} and Sheila Jenkins and Barkovich, {Anthony J.} and Sakir Gultekin and Joel Kramer and Mary Crittenden and Matthay, {Katherine K.}",
year = "2001",
doi = "10.1067/mpd.2001.118200",
language = "English (US)",
volume = "139",
pages = "552--559",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome

T2 - Relationship to MRI findings and anti-neuronal antibodies

AU - Hayward, Kristen

AU - Jeremy, Rita J.

AU - Jenkins, Sheila

AU - Barkovich, Anthony J.

AU - Gultekin, Sakir

AU - Kramer, Joel

AU - Crittenden, Mary

AU - Matthay, Katherine K.

PY - 2001

Y1 - 2001

N2 - Objectives: Opsoclonus-myoclonus-ataxia (OMA) syndrome affects 2% to 3% of patients with neuroblastoma. This study examined relationships between long-term neurobehavioral outcomes and potential biologic markers of OMA, including chronic changes on magnetic resonance imaging (MRI) brain scanning and prevalence of late antineuronal antibodies. Study design: Children with neuroblastoma and OMA were identified through medical record review of patients treated at the University of California at San Francisco Medical Center from 1979 to 1999. Eleven patients with a mean follow-up time of 7.6 years underwent standard neurologic, neurocognitive/developmental, behavioral, and academic assessments. Consenting patients underwent MRI brain scanning and a blood draw. Sera were analyzed for the presence of antineuronal immunoreactivity. Results: Two (18%) patients had no observed neurologic abnormalities, 7 (64%) demonstrated mild deficits, and 2 (18%) had severe neurologic deficits. However, on neurocognitive, behavioral, and academic assessments, 6 (55%) children performed within the average range, 1 (9%) was moderately below average and 4 (36%) had severe cognitive and behavioral deficiencies. Brain MRI in 5 of 5 patients was notable for cerebellar atrophy without supratentorial involvement. Antineuronal activity was detected in sera of 0 of 10 children at follow-up. Conclusions: Certain patients with neuroblastoma associated OMA may achieve average-range neurobehavioral function in spite of residual neurologic abnormalities, with suggestion of continued improvement over time. Late cerebellar atrophy appears to be a common finding regardless of neurologic outcome, whereas antineuronal immune reactivity does not appear to be a long-term feature of OMA.

AB - Objectives: Opsoclonus-myoclonus-ataxia (OMA) syndrome affects 2% to 3% of patients with neuroblastoma. This study examined relationships between long-term neurobehavioral outcomes and potential biologic markers of OMA, including chronic changes on magnetic resonance imaging (MRI) brain scanning and prevalence of late antineuronal antibodies. Study design: Children with neuroblastoma and OMA were identified through medical record review of patients treated at the University of California at San Francisco Medical Center from 1979 to 1999. Eleven patients with a mean follow-up time of 7.6 years underwent standard neurologic, neurocognitive/developmental, behavioral, and academic assessments. Consenting patients underwent MRI brain scanning and a blood draw. Sera were analyzed for the presence of antineuronal immunoreactivity. Results: Two (18%) patients had no observed neurologic abnormalities, 7 (64%) demonstrated mild deficits, and 2 (18%) had severe neurologic deficits. However, on neurocognitive, behavioral, and academic assessments, 6 (55%) children performed within the average range, 1 (9%) was moderately below average and 4 (36%) had severe cognitive and behavioral deficiencies. Brain MRI in 5 of 5 patients was notable for cerebellar atrophy without supratentorial involvement. Antineuronal activity was detected in sera of 0 of 10 children at follow-up. Conclusions: Certain patients with neuroblastoma associated OMA may achieve average-range neurobehavioral function in spite of residual neurologic abnormalities, with suggestion of continued improvement over time. Late cerebellar atrophy appears to be a common finding regardless of neurologic outcome, whereas antineuronal immune reactivity does not appear to be a long-term feature of OMA.

UR - http://www.scopus.com/inward/record.url?scp=0034781738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034781738&partnerID=8YFLogxK

U2 - 10.1067/mpd.2001.118200

DO - 10.1067/mpd.2001.118200

M3 - Article

C2 - 11598603

AN - SCOPUS:0034781738

VL - 139

SP - 552

EP - 559

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 4

ER -